摘要
目的:开展培元化瘀解毒方联合新辅助化疗治疗进展期胃癌患者的对照研究,探究培元化瘀解毒方的临床疗效及安全性。方法:采用真实世界研究方法,尊重患者意愿,将纳入的64例进展期胃癌患者分为对照组和中西医联合组各32例。对照组给予奥沙利铂和替吉奥联合的SOX术前新辅助化疗方案;中西医联合组在化疗基础上联合使用培元化瘀解毒方;两组完成新辅助化疗后行胃癌手术。比较两组患者肿瘤退缩分级、疗效评价、中医证候积分、功能状态KPS评分、肿瘤标志物、血细胞计数及肝肾功能。结果:治疗后,与对照组相比,中西医联合组肿瘤退缩分级有效率更高(P<0.05)。中医证候方面,中西医联合组治疗前后的胃痛、腹胀、食少、呕吐、便溏、乏力评分,差异有统计学意义(P<0.05)。中西医联合组治疗后中医证候总积分和功能状态KPS评分明显改善,优于对照组(P<0.05)。而近期疗效、肿瘤标志物、血常规和生化等指标,两组治疗前后均无统计学差异(P>0.05)。结论:培元化瘀解毒方配合新辅助化疗可提高胃癌患者的肿瘤退缩分级,改善患者功能状态评分,提升生活质量,减轻细胞毒药物化疗的不良反应,对进展期胃癌患者起到协同抗肿瘤作用。
Objective:To conduct a controlled study on the combination of Peiyuan Huayu Jiedu formula and neoadjuvant chemotherapy in the treatment of advanced gastric cancer patients,explore the clinical efficacy and safety of Peiyuan Huayu Jiedu formula.Methods:64 patients with advanced gastric cancer were divided into a control group and a combination of traditional Chinese and western medicine group,with 32 patients in each group.The control group was treated with the combination of platinum and fluorouracil.The combination of traditional Chinese and Western medicine group uses the Peiyuan Huayu Jiedu formula on the basis of chemotherapy.Two groups underwent gastric cancer surgery after completing neoadjuvant chemotherapy.Compare the tumor regression grading,efficacy evaluation,traditional Chinese medicine syndrome score,functional status KPS score,tumor markers,blood cell count,and liver and kidney function between two groups of patients.Results:After treatment,compared with the control group,the combined Chinese and Western medicine group had a higher effective rate in tumor regression grading(P<0.05).In terms of traditional Chinese medicine syndromes,there was a statistically significant difference(P<0.05)in the scores of stomach pain,bloating,lack of appetite,vomiting,loose stools,and fatigue before and after treatment in the combined group of traditional Chinese and western medicine.After treatment with the combination of traditional Chinese and Western medicine,the total score of traditional Chinese medicine syndromes and the KPS score of functional status were significantly improved(P<0.05).However,there was no significant difference in recent efficacy,tumor markers,blood routine and biochemical indicators between the two groups before and after treatment(P>0.05).Conclusion:Peiyuan Huayu Jiedu formula combined with neoadjuvant chemotherapy can improve the tumor regression grade of gastric cancer patients,improve their functional status KPS score,improve their quality of life,alleviate the adverse reactions of cyto
作者
金蕊
何卫才
郭甲民
王颖栋
马龙安
袁彬
雎岩
陈晓泉
赵培西
JIN Rui;HE Weicai;GUO Jiamin;WANG Yingdong;MA Longan;YUAN Bin;JU Yan;CHEN Xiaoquan;ZHAO Peixi(Department of Pharmacy,Shaanxi Cancer Hospital,Xi’an 710061,China)
出处
《陕西中医》
CAS
2023年第9期1227-1230,共4页
Shaanxi Journal of Traditional Chinese Medicine
基金
陕西省中医药管理局中医药传承创新暨秦药开发项目(2021-01-ZZ-012)。
关键词
胃癌
培元化瘀解毒方
新辅助化疗
对照研究
证候
抗肿瘤
Gastric cancer
Peiyuan Huayu Jiedu formula
Neoadjuvant chemotherapy
Control study
Symptoms
Anti-tumor
